



(51) International Patent Classification:

C07D 413/14 (2006.01) *A61K 31/497* (2006.01)
A61K 31/4245 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4196 (2006.01)

(21) International Application Number:

PCT/GB2014/050163

(22) International Filing Date:

22 January 2014 (22.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13305078.1 23 January 2013 (23.01.2013) EP

(71) Applicant (for all designated States except MG): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London Greater London W2 6BD (GB).

(72) Inventors: **BARLAAM, Bernard Christophe**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SG10 4TG (GB). **BERRY, David**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **DELOUVRIE, Benedicte**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **HARRIS, Craig Steven**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **LAMBERT-VAN DER BREMPT, Christine Marie Paul**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **OUVRY, Gilles**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alder-

ley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **REID, Gary Patrick**; Onyx Scientific Limited, Silverbriar, Sunderland Enterprise East, Sunderland Tyne and Wear SR5 2TQ (GB). **TOMKINSON, Gary Peter**; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Alderley Park, Macclesfield, Cheshire, SK10 4TG (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CHEMICAL COMPOUNDS



(57) Abstract: The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R¹ and R² have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.